Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 6 · 85.7%High 0 · 0%

Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic

ACR 50% improvement · patients with rheumatoid arthritis

Abatacept (2 and 10mg/kg) + DMARDs/biologic probably leads to higher ACR 50% improvement compared with placebo + DMARDs/biologic (moderate certainty).

1 finding from 1 review

Abatacept for rheumatoid arthritis 2009 · Cochrane Headline outcomes only
RR 2.21 [1.73, 2.82]
3 studies · 993 participants
Moderate

Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic

Pain Visual analog scale Scale from 0 to 100 (lower is better) · patients with rheumatoid arthritis

1 finding from 1 review

Abatacept for rheumatoid arthritis 2009 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1425 participants
Moderate

Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic

Physical function · patients with rheumatoid arthritis

Abatacept (2 and 10mg/kg) + DMARDs/biologic probably leads to higher improvement in physical function (HAQ: greater than 0.3 increase… compared with placebo + DMARDs/biologic (moderate certainty).

1 finding from 1 review

Abatacept for rheumatoid arthritis 2009 · Cochrane Headline outcomes only
RR 1.62 [1.35, 1.95]
1 study · 638 participants
Moderate

Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic

Achievement of low disease activity state (DAS 28 less than 3.2, scale 0‐10) · patients with rheumatoid arthritis

Abatacept (2 and 10mg/kg) + DMARDs/biologic probably leads to higher achievement of low disease activity state (DAS 28 less than 3.2,… compared with placebo + DMARDs/biologic (moderate certainty).

1 finding from 1 review

Abatacept for rheumatoid arthritis 2009 · Cochrane Headline outcomes only
RR 4.33 [2.84, 6.59]
1 study · 638 participants
Moderate

Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic

Total serious adverse events · patients with rheumatoid arthritis

Abatacept (2 and 10mg/kg) + DMARDs/biologic showed no clear difference in total serious adverse events compared with placebo + DMARDs/biologic (moderate certainty).

1 finding from 1 review

Abatacept for rheumatoid arthritis 2009 · Cochrane Headline outcomes only
RR 1.05 [0.87, 1.28]
6 studies · 3151 participants
Moderate

Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic

Radiographic progression · patients with rheumatoid arthritis

1 finding from 1 review

Abatacept for rheumatoid arthritis 2009 · Cochrane Headline outcomes only
no estimate extracted
1 study · 586 participants
Moderate

Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic

Long‐term serious adverse events · patients with rheumatoid arthritis

1 finding from 1 review

Abatacept for rheumatoid arthritis 2009 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 950 participants
Low